Cybin Inc (CYBN) Stock Price, Quote & News

Company Profile

Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical...

Industry: Biotechnology

Sector: Healthcare

Website: cybin.com

Address:

100 King Street West, Suite 5600, Toronto, Canada

a_rational_investor Dec. 10 at 5:01 PM

$CYBN any news? Sector news?

1 · Reply

HedgeAlerts Dec. 9 at 9:45 PM

Hedge Alert Live - Protect Your Portfolio Contract: $CYBN $5.00 Put · DEC 19, 2025 Exp Entry Price: $0.06 - $0.15 Exit Price Target: $0.11 Profit Margin: +88% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Rico_Again_Jorge Dec. 9 at 9:27 PM

$CYBN Unloading zone

0 · Reply

microdoseme Dec. 8 at 8:18 PM

$CYBN https://www.msn.com/en-us/health/other/psilocybin-helps-the-brain-unlearn-fear-by-silencing-specific-neural-pathways/ar-AA1RWpp8?ocid=socialshare

0 · Reply

ChristopherMcC Dec. 8 at 7:42 PM

$CYBN oh compass up 7%. Mind med up 7%. Atai up 3%. ..wonder how Cybin's doing.

2 · Reply

thepalace2007 Dec. 8 at 1:28 AM

$CYBN loading zone

0 · Reply

microdoseme Dec. 5 at 7:47 PM

$CYBN https://open.substack.com/pub/themicrodose/p/federal-government-announces-new?utm_campaign=post&utm_medium=email

0 · Reply

BobJohnBuoy666 Dec. 5 at 6:49 PM

$CYBN working on a doji for weekly close. I could see a case for another push above 6.50s next week.

0 · Reply

BRITLS Dec. 5 at 3:26 PM

$CYBN good swing trade lately for me

0 · Reply

microdoseme Dec. 5 at 2:47 PM

$CYBN 2026 year of the psychedelics. Hopefully relief for our veterans and anyone dealing with depression. These will be gamechangers. Onegamechangers.One One aspect I learned from psychedelics a long time ago. If done right, it could change humanity. These are truly healing drugs.

0 · Reply

Cybin Inc. (CYBN) Q2 2026 Earnings Call Transcript

Nov 13, 2025, 7:20 AM EST - 27 days ago

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Nov 12, 2025, 7:30 AM EST - 4 weeks ago

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Nov 6, 2025, 7:30 AM EST - 4 weeks ago

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Nov 5, 2025, 7:30 AM EST - 5 weeks ago

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 7:30 AM EST - 5 weeks ago

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Oct 31, 2025, 4:19 PM EDT - 5 weeks ago

Cybin Announces Closing of $175 Million Registered Direct Offering

Oct 28, 2025, 8:00 AM EDT - 6 weeks ago

Cybin Announces $175 Million Registered Direct Offering

Oct 21, 2025, 8:00 AM EDT - 7 weeks ago

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Sep 23, 2025, 5:00 PM EDT - 2 months ago

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

Sep 11, 2025, 3:59 PM EDT - 3 months ago

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm

Sep 11, 2025, 7:30 AM EDT - 3 months ago

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 8, 2025, 7:30 AM EDT - 3 months ago

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Sep 4, 2025, 7:30 AM EDT - 3 months ago

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:30 AM EDT - 3 months ago

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Sep 2, 2025, 7:30 AM EDT - 3 months ago

Cybin Announces Senior Leadership Changes

Aug 26, 2025, 7:30 AM EDT - 3 months ago

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 18, 2025, 5:30 PM EDT - 4 months ago

Cybin Announces Results of Annual Meeting of Shareholders

Aug 13, 2025, 5:30 PM EDT - 4 months ago

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Aug 7, 2025, 7:30 AM EDT - 4 months ago

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 6, 2025, 7:30 AM EDT - 4 months ago

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jul 17, 2025, 7:30 AM EDT - 5 months ago

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jul 1, 2025, 11:19 AM EDT - 5 months ago

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 30, 2025, 10:03 PM EDT - 5 months ago

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Jun 30, 2025, 9:27 PM EDT - 5 months ago

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 13, 2025, 7:45 AM EDT - 6 months ago

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Jun 12, 2025, 7:30 AM EDT - 6 months ago

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Jun 11, 2025, 7:30 AM EDT - 6 months ago

Cybin to Participate in the 2025 Psychedelic Science Conference

Jun 3, 2025, 7:30 AM EDT - 6 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

May 22, 2025, 7:30 AM EDT - 7 months ago

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

May 20, 2025, 7:30 AM EDT - 7 months ago

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

May 15, 2025, 7:30 AM EDT - 7 months ago

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

May 14, 2025, 7:30 AM EDT - 7 months ago

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

May 8, 2025, 7:30 AM EDT - 7 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

May 1, 2025, 7:30 AM EDT - 7 months ago

Cybin to Participate at the 28th Annual Milken Institute Global Conference

Apr 23, 2025, 7:30 AM EDT - 8 months ago

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Apr 21, 2025, 8:00 AM EDT - 8 months ago

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

Feb 10, 2025, 9:48 PM EST - 10 months ago

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Jan 15, 2025, 12:07 PM EST - 11 months ago

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jan 13, 2025, 7:30 AM EST - 11 months ago

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Jan 9, 2025, 5:00 PM EST - 11 months ago

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Dec 10, 2024, 7:30 AM EST - 1 year ago

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

Dec 4, 2024, 7:30 AM EST - 1 year ago

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

Nov 18, 2024, 7:00 AM EST - 1 year ago

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Nov 14, 2024, 7:30 AM EST - 1 year ago

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

Nov 13, 2024, 7:30 AM EST - 1 year ago

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Cybin to Participate at the 2024 Milken Institute Future of Health Summit

a_rational_investor Dec. 10 at 5:01 PM

$CYBN any news? Sector news?

1 · Reply

HedgeAlerts Dec. 9 at 9:45 PM

0 · Reply

Rico_Again_Jorge Dec. 9 at 9:27 PM

$CYBN Unloading zone

0 · Reply

microdoseme Dec. 8 at 8:18 PM

$CYBN https://www.msn.com/en-us/health/other/psilocybin-helps-the-brain-unlearn-fear-by-silencing-specific-neural-pathways/ar-AA1RWpp8?ocid=socialshare

0 · Reply

ChristopherMcC Dec. 8 at 7:42 PM

$CYBN oh compass up 7%. Mind med up 7%. Atai up 3%. ..wonder how Cybin's doing.

2 · Reply

thepalace2007 Dec. 8 at 1:28 AM

$CYBN loading zone

0 · Reply

microdoseme Dec. 5 at 7:47 PM

$CYBN https://open.substack.com/pub/themicrodose/p/federal-government-announces-new?utm_campaign=post&utm_medium=email

0 · Reply

BobJohnBuoy666 Dec. 5 at 6:49 PM

$CYBN working on a doji for weekly close. I could see a case for another push above 6.50s next week.

0 · Reply

BRITLS Dec. 5 at 3:26 PM

$CYBN good swing trade lately for me

0 · Reply

microdoseme Dec. 5 at 2:47 PM

0 · Reply

terrapin22 Dec. 5 at 5:02 AM

$CYBN

0 · Reply

BobJohnBuoy666 Dec. 5 at 3:01 AM

$CYBN love this price action

0 · Reply

ChristopherMcC Dec. 4 at 1:25 PM

$CYBN update... .... ... .. . ok. Maybe not an update. Reiteration.

0 · Reply

HedgeAlerts Dec. 4 at 7:11 AM

Hedge Alert Live - Protect Your Portfolio Contract: $CYBN $5.00 Put · DEC 19, 2025 Exp Entry Price: $0.20 - $0.20 Exit Price Target: $0.39 Profit Margin: +97% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply